Abstract
Multiple lines of evidence suggest that a dysfunction in the glutamatergic neurotransmission via the N-methyl- D-aspartate (NMDA) receptors contributes to the pathophysiology of psychiatric diseases including schizophrenia. The potentiation of NMDA receptor function may be a useful approach for the treatment of diseases associated with NMDA receptor hypofunction. One possible strategy is to increase synaptic levels of glycine by blocking the glycine transporter-1 (GlyT-1) in glia cells, since glycine acts as a co-agonist site on the NMDA receptor. In this article, the author reviews the recent important patents on GlyT-1 inhibitors for treatment of schizophrenia and other psychiatric diseases associated with the NMDA receptor hypofunction.
Keywords: NMDA receptor, glycine, glycine transporter, glia, cognition, schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued)
Title: Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia
Volume: 1 Issue: 1
Author(s): Kenji Hashimoto
Affiliation:
Keywords: NMDA receptor, glycine, glycine transporter, glia, cognition, schizophrenia
Abstract: Multiple lines of evidence suggest that a dysfunction in the glutamatergic neurotransmission via the N-methyl- D-aspartate (NMDA) receptors contributes to the pathophysiology of psychiatric diseases including schizophrenia. The potentiation of NMDA receptor function may be a useful approach for the treatment of diseases associated with NMDA receptor hypofunction. One possible strategy is to increase synaptic levels of glycine by blocking the glycine transporter-1 (GlyT-1) in glia cells, since glycine acts as a co-agonist site on the NMDA receptor. In this article, the author reviews the recent important patents on GlyT-1 inhibitors for treatment of schizophrenia and other psychiatric diseases associated with the NMDA receptor hypofunction.
Export Options
About this article
Cite this article as:
Hashimoto Kenji, Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia, Recent Patents on CNS Drug Discovery (Discontinued) 2006; 1 (1) . https://dx.doi.org/10.2174/157488906775245336
DOI https://dx.doi.org/10.2174/157488906775245336 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Acknowledgements to Reviewers
Current Alzheimer Research Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Medical Management of Obesity
Current Nutrition & Food Science 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design The Role of Binding Kinetics in GPCR Drug Discovery
Current Topics in Medicinal Chemistry Environmentally Friendly Suzuki Aryl-Aryl Cross-Coupling Reaction
Current Organic Chemistry High Throughput Sonication: Evaluation for Compound Solubilization
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Treatment of Insulin Resistance in the Neurodegeneration
Recent Patents on CNS Drug Discovery (Discontinued) The Effects of Tamoxifen on Immunity
Current Medicinal Chemistry Copper (II) Complexes of [1,2,4]Triazolo [1,5-a]Pyrimidine Derivatives as Potential Anti-Parasitic Agents
Drug Metabolism Letters Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology